Union of Kansai Governments: Kansai Deep Tech Ecosystem Gains Global Visibility
31.3.2026 02:00:00 CEST | Business Wire | Press release
Platform Update Reflects 20-Place Rise in GSER Ranking
The Union of Kansai Governments has refreshed the Kansai Startup Ecosystem portal, strengthening the region’s global communication platform for startups and deep tech.
At the same time, the “DeepTech Frontier Kansai” website has also been updated, further enhancing international visibility for Kansai’s rapidly growing deep tech ecosystem.
Kansai’s startup ecosystem has demonstrated steady growth in recent years. The ecosystem’s total value expanded from USD 2.68 billion in 2023 to USD 3.23 billion in 2025. In addition, Kansai rose 20 places in the Global Startup Ecosystem Ranking (GSER) published by Startup Genome, climbing from 99th in 2023 to 79th in 2025, and early-stage funding reached USD 124 million.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330459051/en/
Kansai’s Strength in Deep Tech
Kansai represents a rare ecosystem where fundamental research and industrial application coexist in close geographic proximity, and its concentration of universities, research institutions, and advanced manufacturing industries serves as a key driver of ecosystem growth.
The region has strong global competitiveness across several key fields, including:
• Life Sciences (regenerative medicine, drug discovery, medical devices)
• Green Tech (next-generation energy, storage batteries, and advanced materials)
• Advanced Digital Technologies (AI, quantum computing, robotics, Web3)
University-originated research is increasingly being commercialized through startups, reinforcing Kansai’s position as a research-driven deep tech ecosystem.
Bridging the Visibility Gap
Despite its growth, Kansai remains relatively underrecognized on the global stage compared with similarly sized economic regions around the world. It is therefore important to communicate the region’s achievements more strategically to global audiences, including the number of startups created and the amount of funding raised, and to further enhance its international visibility.
Strengthening Global Outreach: DeepTech Frontier Kansai
In response to these challenges, the Union of Kansai Governments announced its strategic direction for international communication at the Osaka Climate Innovation Forum, held during the Global Startup Crossroads Osaka event on September 18, 2025.
This initiative led to the development of the Kansai Startup Ecosystem Communication Strategy (2025–2029).
Under the “DeepTech Frontier Kansai” brand, the region is strengthening its global presence through:
• Driving brand awareness and engagement for DeepTech Frontier Kansai
• Curating information on regional startups and their strategic potential
• Leveraging global databases to boost international visibility and outreach
The strategy organizes startup funding data, valuation metrics, and research achievements into a structured and continuously updated English-language communication framework.
Entering a New Phase of Global Engagement
Kansai is now accelerating its connections with international investors and global innovation networks, with deep tech at the core of this effort.
The updated websites serve as foundational platforms for visualizing the region’s ecosystem and creating tangible opportunities for global collaboration.
Through these initiatives, Kansai aims to deepen dialogue with global investors, corporations, and ecosystem partners, marking the beginning of a new phase in its growth as an internationally connected deep tech hub.
Learn More
Kansai Startup Ecosystem Portal
https://kansai-startup-ecosystem.com/en/
DeepTech Frontier Kansai
https://osaka-startup.com/deeptech-frontier/en/
About Union of Kansai Governments
The Union of Kansai Governments is a regional administrative organization comprising eight prefectures—Osaka, Kyoto, Hyogo, Shiga, Nara, Wakayama, Tottori, and Tokushima—and four designated cities: Kyoto, Osaka, Sakai, and Kobe. The organization promotes cross-regional policy coordination to enhance economic development and global competitiveness across the Kansai region.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260330459051/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom